Evidence map›Paper›PMID 35650638›Full record

Observational studyArthritis research & therapy2022

Clinical course of patients with rheumatoid arthritis who continue or discontinue biologic therapy after hospitalization for infection: a retrospective observational study.

Yusuke Kashiwado, Chikako Kiyohara, Yasutaka Kimoto, Shuji Nagano, Takuya Sawabe, Kensuke Oryoji, Shinichi Mizuki, Hiroaki Nishizaka, Seiji Yoshizawa, Shigeru Yoshizawa and 10 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Arthritis research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 13 institutions in 1 country.

Yusuke KashiwadoDepartment of Internal Medicine, Kyushu University Beppu Hospital, 4546 Tsurumibaru, Beppu, Oita, 874-0838, Japan.
Chikako KiyoharaDepartment of Preventive Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yasutaka KimotoDepartment of Internal Medicine, Kyushu University Beppu Hospital, 4546 Tsurumibaru, Beppu, Oita, 874-0838, Japan.
Shuji NaganoDepartment of Rheumatology, Aso Iizuka Hospital, Iizuka, Japan.
Takuya SawabeDepartment of Rheumatology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Kensuke OryojiThe Center for Rheumatic Diseases, Matsuyama Red Cross Hospital, Matsuyama, Japan.
Shinichi MizukiThe Center for Rheumatic Diseases, Matsuyama Red Cross Hospital, Matsuyama, Japan.
Hiroaki NishizakaDepartment of Rheumatology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
Seiji YoshizawaDepartment of Rheumatology, Hamanomachi Hospital, Fukuoka, Japan.
Shigeru YoshizawaDepartment of Rheumatology, National Hospital Organization Fukuoka Hospital, Fukuoka, Japan.
Tomomi TsuruDepartment of Rheumatology, Med.Co. LTA PS Clinic, Fukuoka, Japan.
Yasushi InoueDepartment of Rheumatology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan.
Naoyasu UedaDepartment of Rheumatology and Infection, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan.
Shun-Ichiro OtaDepartment of Rheumatology, Internal medicine and connective tissue disorders, Shimonoseki City Hospital, Shimonoseki, Japan.
Yasuo SuenagaDepartment of Rheumatology, Beppu Medical Center, NHO, Beppu, Japan.
Tomoya MiyamuraDepartment of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Yoshifumi TadaDepartment of Rheumatology, Saga University Hospital, Saga, Japan.
Hiroaki NiiroDepartment of Medical Education, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Koichi AkashiDepartment of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Takahiko HoriuchiDepartment of Internal Medicine, Kyushu University Beppu Hospital, 4546 Tsurumibaru, Beppu, Oita, 874-0838, Japan. horiuchi@beppu.kyushu-u.ac.jp.ORCID 0000-0002-1770-1087
Kyushu University · JPKyushu University Beppu Hospital · JPFukuoka Hospital · JPMatsuyama Red Cross Hospital · JPAso Iizuka Hospital · JPBeppu Medical Center · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPJapanese Red Cross Fukuoka Hospital · JPKitakyushu Municipal Medical Center · JPMiyazaki Prefectural Hospital · JPNational Kyushu Medical Center · JPSaga University · JPShimonoseki City Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo analyse the subsequent clinical course of patients with rheumatoid arthritis (RA) who either continued or discontinued biologic agents after hospitalization for infections.

methodsWe retrospectively reviewed the clinical records of 230 RA patients with 307 hospitalizations for infections under biologic therapy between September 2008 and May 2014 in 15 institutions for up to 18 months after discharge. The risks of RA flares and subsequent hospitalizations for infections from 61 days to 18 months after discharge were evaluated.

resultsSurvival analyses indicated that patients who continued biologic therapy had a significantly lower risk of RA flares (31.4% vs. 60.6%, P < 0.01) and a slightly lower risk of subsequent infections (28.7% vs. 34.5%, P = 0.37). Multivariate analysis showed that discontinuation of biologic therapy, diabetes, and a history of hospitalization for infection under biologic therapy were associated with RA flares. Oral steroid therapy equivalent to prednisolone 5 mg/day or more and chronic renal dysfunction were independent risk factors for subsequent hospitalizations for infections.

conclusionsDiscontinuation of biologic therapy after hospitalization for infections may result in RA flares. Continuation of biologic therapy is preferable, particularly in patients without immunodeficiency.

Indexed as

Arthritis, RheumatoidBiological TherapyHospitalizationHumansRetrospective StudiesRisk FactorsAntirheumatic agentsBiological therapyInfectionRheumatoid arthritis

Identifiers

PMID35650638
PMCPMC9158270
OpenAlexW4281955793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.